November 09, 2011 08:30 AM Eastern Time
Plasma Surgical Introduces the New PlasmaJet® Ultra at Annual AAGL meeting
ROSWELL, Ga.--(BUSINESS WIRE)--Plasma Surgical announced today the introduction of its PlasmaJet® Ultra System for hemostatic cutting and coagulation during this week's 40th Global Congress of Minimally Invasive Gynecology sponsored by the American Association of Gynecologic Laparoscopists (AAGL) being held in Hollywood, Florida.
The introduction of the PlasmaJet Ultra marks a significant advancement in Plasma Surgical's tissue sparing technology for open and laparoscopic surgical procedures. Designed to maintain a thin, hemostatic layer of tissue during surgical cutting, ablation and coagulation, the PlasmaJet Ultra offers surgeons a precise method for treating tissues with minimal damage to adjacent and underlying structures.
"The PlasmaJet Ultra offers surgeons an option for precise cutting and coagulation of tissue and the ability to excise or ablate endometriosis and endometriomas without the risk of damage to sensitive tissues and organs in close proximity to the tissue being removed," stated Ceana Nezhat, M.D., F.A.C.O.G., F.A.C.S., Director of the Atlanta Center for Special Pelvic Surgery and Reproductive Medicine. "The device is also extremely versatile since it can be utilized for both open and laparoscopic surgical procedures".
The AAGL meeting will also feature a presentation by Dr. Nicholas Hill from the Department of Obstetrics and Gynaecology, Princess Royal University Hospital, Kent, U.K., on the use of the PlasmaJet Ultra for the treatment of endometriosis.
"The PlasmaJet System is already distinguished as a new technology for the cutting and coagulation of all tissues," said Peter Gibson, President and Chief Executive Officer of Plasma Surgical in a statement. "The PlasmaJet Ultra further optimizes the approach to provide a virtual scalpel with a more precise cut surrounded by a more effective zone of coagulation capability."
About the PlasmaJet® Ultra System
The PlasmaJet Ultra System is a neutral plasma surgery system that has both U.S. FDA 501(k) clearance and European CE Mark. The device, which is indicated for cutting and coagulation of tissue in open and laparoscopic surgery, provides surgeons with an electrically neutral surgical option that does not require a grounding pad, and eliminates the risk of alternate site burns. Clinical results with PlasmaJet System have been reported in almost 50 peer-reviewed publications and presentations at scientific meetings to date, including the use of the technology for a variety of gynecologic, oncologic, hepatic, orthopedic, and plastic surgery procedures.
About Plasma Surgical
Founded in 2000, Plasma Surgical is a global company committed to advancing surgical technology that enhances the care and safety of patients during medical procedures. The company's most revolutionary enhancement is the application of plasma surgery, where pure plasma is used to efficiently cut and coagulate tissue.
For more information visit plasmasurgical.com
Peter Gibson, President and Chief Executive Officer, +1-678-578-4390